Limit on lab-grown human embryos dropped by stem-cell body
By Nidhi Subbaraman,
Nature
| 05. 26. 2021
The International Society for Stem Cell Research relaxed the famous 14-day rule on culturing human embryos in its latest research guidelines.
The international body representing stem-cell scientists has torn up a decades-old limit on the length of time that scientists should grow human embryos in the lab, giving more leeway to researchers who are studying human development and disease.
Previously, the International Society for Stem Cell Research (ISSCR) recommended that scientists culture human embryos for no more than two weeks after fertilization. But on 26 May, the society said it was relaxing this famous limit, known as the ‘14-day rule’. Rather than replace or extend the limit, the ISSCR now suggests that studies proposing to grow human embryos beyond the two-week mark be considered on a case-by-case basis, and be subjected to several phases of review to determine at what point the experiments must be stopped.
The ISSCR made this change and others to its guidelines for biomedical research in response to rapid advances in the field, including the ability to create embryo-like structures from human stem cells. In addition to relaxing the ‘14-day rule’, for instance, the group advises against editing genes in human embryos until the safety of genome...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...